Testing effectiveness (Phase 2)Study completedNCT01594216
What this trial is testing
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Who this might be right for
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine 25